دورية أكاديمية
Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.
| العنوان: | Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures. |
|---|---|
| المؤلفون: | Stepanenko AA; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia.; Department of Medical Nanobiotechnology, Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical University, The Ministry of Health of the Russian Federation, Ostrovitianov Str. 1, 117997 Moscow, Russia., Sosnovtseva AO; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia., Valikhov MP; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia.; Department of Medical Nanobiotechnology, Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical University, The Ministry of Health of the Russian Federation, Ostrovitianov Str. 1, 117997 Moscow, Russia., Chernysheva AA; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia., Cherepanov SA; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia., Yusubalieva GM; Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Russia., Ruzsics Z; Institute of Virology, Medical Center, University of Freiburg, Freiburg, Germany.; Faculty of Medicine, University of Freiburg, Freiburg, Germany., Lipatova AV; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia., Chekhonin VP; Department of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky Lane 23, 119034 Moscow, Russia.; Department of Medical Nanobiotechnology, Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical University, The Ministry of Health of the Russian Federation, Ostrovitianov Str. 1, 117997 Moscow, Russia. |
| المصدر: | Molecular therapy oncolytics [Mol Ther Oncolytics] 2021 Dec 21; Vol. 24, pp. 230-248. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Cambridge, MA : Cell Press Original Publication: New York, NY : Nature Publishing Group, [2014]-[2023] |
| مستخلص: | Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd) for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35, Ad5/3RGD, and Ad5/35RGD, all harboring the delta-24 modification) and compared their infectivity, replication, reproduction, and cytolytic efficacy in human and rodent glioma cell lines and short-term cultures from primary gliomas. In human cells, both Ad5/35-delta-24 and Ad5/3-delta-24 displayed superior infectivity and cytolytic efficacy over Ad5-delta-24-RGD, while Ad5/3-delta-24-RGD and Ad5/35-delta-24-RGD did not show further improvements in efficacy. The expression of the adenoviral receptors/coreceptors CAR, DSG2, and CD46 and the integrins αVβ3/αVβ5 did not predict the relative cytolytic efficacy of the fiber-modified rAds. The cytotoxicity of the fiber-modified rAds in human primary normal cultures of different origins and in primary glioma cultures was comparable, indicating that the delta-24 modification did not confer tumor cell selectivity. We also revealed that CT-2A and GL261 glioma cells might be used as murine cell models for the fiber chimeric rAds in vitro and in vivo . In GL261 tumor-bearing mice, Ad5/35-delta-24, armed with the immune costimulator OX40L as the E2A/DBP-p2A-mOX40L fusion, produced long-term survivors, which were able to reject tumor cells upon rechallenge. Our data underscore the potential of local Ad5/35-delta-24-based immunovirotherapy for glioblastoma treatment. Competing Interests: The authors declare no competing interests (© 2021 The Author(s).) |
| References: | Cancer Gene Ther. 2007 Feb;14(2):211-9. (PMID: 17082793) Virology. 2010 Jun 5;401(2):305-13. (PMID: 20347112) J Virol. 2007 Mar;81(6):2688-99. (PMID: 17192304) FEBS Lett. 2019 Dec;593(24):3484-3495. (PMID: 31721176) Methods Mol Biol. 2012;797:21-34. (PMID: 21948466) Cancer Biol Ther. 2003 Sep-Oct;2(5):511-5. (PMID: 14614316) Gene Ther. 2004 Mar;11(6):552-9. (PMID: 14999227) Nat Med. 2011 Jan;17(1):96-104. (PMID: 21151137) Cancer Cell. 2002 May;1(4):325-37. (PMID: 12086848) Gene. 2018 Dec 30;679:11-18. (PMID: 30171937) J Virol. 1996 Oct;70(10):6839-46. (PMID: 8794325) J Med Virol. 2008 Sep;80(9):1595-603. (PMID: 18649343) Metab Eng Commun. 2016 May 12;3:173-186. (PMID: 29468123) Neurooncol Adv. 2019 May-Dec;1(1):vdz009. (PMID: 31608328) Elife. 2017 Apr 19;6:. (PMID: 28414270) Neuro Oncol. 2018 Oct 9;20(11):1494-1504. (PMID: 29796615) Oncogene. 2000 Jan 6;19(1):2-12. (PMID: 10644974) Gene Ther. 2004 Dec;11(23):1694-702. (PMID: 15496964) J Natl Cancer Inst. 2003 May 7;95(9):652-60. (PMID: 12734316) Biotechnology (N Y). 1995 Mar;13(3):265-70. (PMID: 9634769) Hum Gene Ther Methods. 2018 Jun;29(3):124-134. (PMID: 29756505) Int J Mol Sci. 2020 Sep 17;21(18):. (PMID: 32957644) Int J Oncol. 2008 Dec;33(6):1141-7. (PMID: 19020746) Nat Med. 2003 Nov;9(11):1408-12. (PMID: 14566335) J Virol. 2001 Aug;75(16):7602-11. (PMID: 11462032) Oncotarget. 2016 Jun 21;7(25):38210-38223. (PMID: 27203670) Neurosurg Focus. 2021 Feb;50(2):E2. (PMID: 33524943) Cancer Res. 2002 Oct 15;62(20):5736-42. (PMID: 12384532) J Virol Methods. 2013 Sep;192(1-2):28-38. (PMID: 23624118) J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34281988) Gene Ther. 2009 Aug;16(8):1050-7. (PMID: 19516278) Cancer Biol Ther. 2005 Nov;4(11):1203-10. (PMID: 16177567) BMC Biotechnol. 2019 Apr 24;19(1):23. (PMID: 31014302) Oncol Rep. 2005 Oct;14(4):831-5. (PMID: 16142339) Cancer Res. 2004 Aug 15;64(16):5753-9. (PMID: 15313916) Sci Rep. 2021 Aug 9;11(1):16088. (PMID: 34373477) Cancers (Basel). 2018 Dec 05;10(12):. (PMID: 30563098) J Gen Virol. 2004 Sep;85(Pt 9):2627-2638. (PMID: 15302956) Mol Cancer Ther. 2007 Oct;6(10):2728-36. (PMID: 17938266) Nat Med. 2000 Oct;6(10):1134-9. (PMID: 11017145) PLoS One. 2015 Dec 21;10(12):e0145272. (PMID: 26689910) Stem Cells Dev. 2019 Sep 15;28(18):1253-1263. (PMID: 31310179) Virus Res. 2018 Sep 15;257:40-51. (PMID: 30125593) Cancer Res. 1998 Dec 15;58(24):5738-48. (PMID: 9865732) Cancer Res. 2004 Jun 15;64(12):4319-27. (PMID: 15205347) Cancer Gene Ther. 2006 Jul;13(7):696-705. (PMID: 16498429) J Virol. 2000 Mar;74(6):2567-83. (PMID: 10684271) J Virol. 1998 Dec;72(12):9706-13. (PMID: 9811704) Virol J. 2010 Jul 08;7:148. (PMID: 20615244) J Neurosurg. 2000 Jun;92(6):1002-8. (PMID: 10839262) J Invest Dermatol. 2008 Apr;128(4):988-98. (PMID: 17960177) Anal Biochem. 2006 Jul 1;354(1):140-7. (PMID: 16707084) Cancer Gene Ther. 2005 May;12(5):475-86. (PMID: 15706356) Anticancer Res. 2007 Jul-Aug;27(4B):2311-6. (PMID: 17695519) Clin Cancer Res. 2001 Jan;7(1):120-6. (PMID: 11205899) Oncogene. 2010 Aug 19;29(33):4693-704. (PMID: 20543865) J Gene Med. 2007 Sep;9(9):764-78. (PMID: 17640083) Clin Cancer Res. 2006 May 15;12(10):3137-44. (PMID: 16707613) Cancer Res. 2017 Jul 15;77(14):3894-3907. (PMID: 28566332) Int J Cancer. 2003 Mar 1;103(6):723-9. (PMID: 12516090) Science. 2015 Oct 30;350(6260):568-71. (PMID: 26405230) Mol Cancer Ther. 2007 Feb;6(2):742-51. (PMID: 17308070) Expert Opin Drug Deliv. 2016 Jun;13(6):843-58. (PMID: 26967319) J Clin Oncol. 2018 May 10;36(14):1419-1427. (PMID: 29432077) J Gene Med. 2007 Mar;9(3):151-60. (PMID: 17351980) Viruses. 2016 Dec 21;8(12):. (PMID: 28009821) Neurosurg Focus. 2021 Feb;50(2):E3. (PMID: 33524946) J Gene Med. 2009 Nov;11(11):1005-11. (PMID: 19688792) Hum Gene Ther. 2007 Jan;18(1):51-62. (PMID: 17184155) Commun Biol. 2020 Mar 13;3(1):124. (PMID: 32170151) J Virol. 2012 Feb;86(3):1623-37. (PMID: 22130529) Mol Ther. 2004 Oct;10(4):749-57. (PMID: 15451459) Cancer Biol Ther. 2017 Nov 2;18(11):833-840. (PMID: 29144842) Mol Cancer Ther. 2006 Sep;5(9):2408-16. (PMID: 16985075) Transl Oncol. 2017 Oct;10(5):772-779. (PMID: 28797937) |
| فهرسة مساهمة: | Keywords: Ad5-delta-24-RGD; Ad5/3; Ad5/35; DNX-2401; fiber chimeric adenovirus; gene therapy; glioblastoma; glioma; immunotherapy; oncolytic virotherapy |
| تواريخ الأحداث: | Date Created: 20220124 Latest Revision: 20220125 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8761956 |
| DOI: | 10.1016/j.omto.2021.12.013 |
| PMID: | 35071746 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!